Baxter Secures Critical FDA Approval for Clinolipid’s Expanded Use
Baxter International has received FDA approval to expand the use of Clinolipid, a lipid emulsion, to include pediatric patients,...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Authority FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Baxter International has received FDA approval to expand the use of Clinolipid, a lipid emulsion, to include pediatric patients,...
Can-Fite BioPharma has secured approval from the FDA and EMA for a pivotal Phase 3 clinical trial for the...
Merck has terminated a clinical trial arm combining vibostolimab and pembrolizumab for treating resected high-risk melanoma. The decision was...
Takeda Pharmaceutical Company and AC Immune have entered into an exclusive global option and licensing agreement for AC Immune’s...
Flatiron Health, a healthcare technology company, has joined forces with the Association of Cancer Care Centers (ACCC) to improve...
Revance Therapeutics, Inc. has launched DAXXIFY (DaxibotulinumtoxinA-lanm), a novel treatment for cervical dystonia, a painful condition. This marks Revance’s...
Reflow Spur™ Stent Clinical Trial Concludes Enrollment Reflow Medical, Inc. has successfully completed enrollment in the DEEPER REVEAL clinical...
Arcellx and Kite have partnered on the development of anitocabtagene autoleucel (anito-cel), a BCMA CAR T cell therapy for...
Merck’s Phase 3 KEYNOTE-B21 trial has shown that its anti-PD-1 therapy, KEYTRUDA, in combination with chemotherapy, did not improve...
Clinical trials have demonstrated the significant potential of SPT-300, an oral prodrug of the neurosteroid allopregnanolone. The Glyph™ platform...